CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.

European Journal of Haematology
Anne Mette BuhlHenrik Leffers

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course. IgV(H) mutational status, chromosomal aberrations, CD38 expression and ZAP-70 expression are prognostic markers in CLL, however, they are not exclusively confined to this disease. We recently identified a novel CLL-specific gene (CLL upregulated gene1, CLLU1) that is exclusively upregulated in CLL cells. Here we describe our evaluation of the prognostic significance of CLLU1 in CLL. A cohort of 59 previously untreated CLL patients was studied. We determined the expression levels of two CLLU1 transcripts, cDNA1 and CDS, by quantitative RT-PCR. The relation between CLLU1 expression and time to therapy, overall survival and presence or absence of ZAP-70, CD38, chromosomal aberrations or IgV(H) mutations in the 59 patients was analyzed. Analyzed as a continuous, quantitative parameter CLLU1 levels significantly predicted time from diagnosis to initiation of therapy (P < or = 0.0003) Analyzed as a categorical parameter, by segregation of the patients into groups with cDNA1 or CDS expression above or below the median, the CLLU1 levels significantly predicted time from diagnosis to initiation of therapy (P = 0.001) and predicted overall ...Continue Reading

References

Sep 13, 1990·The New England Journal of Medicine·G JuliussonG Gahrton
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Caligaris-Cappio, T J Hamblin
Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Apr 23, 2003·Immunity·Edina SchweighofferVictor L J Tybulewicz
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yuri VasconcelosGuillaume Dighiero
Jan 17, 2004·Lancet·Jenny A OrchardDavid G Oscier
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian HaslingerRoger Abseher
Oct 19, 2004·American Journal of Clinical Pathology·Stephen J SupEric D Hsi
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Apr 2, 2005·Blood·Pablo OppezzoUNKNOWN French Cooperative Group on CLL
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aparna RavalChristoph Plass
Jun 3, 2005·The Journal of Clinical Investigation·Cristina ScielzoFederico Caligaris-Cappio

❮ Previous
Next ❯

Citations

Sep 6, 2007·Leukemia & Lymphoma·Andreas Rosenwald
Mar 14, 2013·Leukemia & Lymphoma·Richard RosenquistRebeqa Gunnarsson
Jun 29, 2012·Leukemia Research·Elisabeth Oppliger LeibundgutGabriela M Baerlocher
Aug 25, 2009·Best Practice & Research. Clinical Haematology·Carles CodonyFrancesc Bosch
Jul 5, 2008·Blood Reviews·Femke Van BockstaeleJan Philippé
Jul 22, 2006·European Journal of Haematology·Lukas Smolej
Feb 18, 2011·European Journal of Haematology·Anne Mette BuhlThomas J Kipps
Jan 17, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Nicola Cahill, Richard Rosenquist
Jan 26, 2012·Expert Review of Hematology·Marie SevovLarry Mansouri
Jul 21, 2016·Infectious Agents and Cancer·A P Kozlov

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.